Biopharma · global
HER2-Positive Breast Cancer Drug Pipeline Heats Up, With the Next Round of Competition Targeting More Precise Tumor Vulnerabilities
As HER2-targeted therapies have already reshaped breast cancer prognosis, the focus of pharmaceutical competition is no longer simply whether HER2 can be hit, but how to find a more effective and tolerable treatment position among antibodies, bispecific designs, and antibody-drug conjugates.
HER2-positive breast cancer was once a breast cancer subtype associated with higher malignancy and concerning recurrence risk. But after the emergence of targeted drugs such as trastuzumab, it also became one of the most representative success stories in precision oncology. Today, the questions in this field have shifted from whether a target is available to more nuanced clinical challenges: how to sequence treatment after patients have received multiple lines of therapy, how to manage brain metastases, and whether new drugs can reduce toxicity and treatment burden in addition to improving efficacy.
According to DelveInsight information carried by Barchart, the HER2-positive breast cancer drug development pipeline is accelerating, with more than 50 pharmaceutical and biotech companies investing in candidate drugs and preparing to advance into future market competition. DelveInsight’s 2026 pipeline report page also lists a similar scale, saying it covers more than 50 companies and more than 55 pipeline drugs, spanning clinical and nonclinical products, different development stages, routes of administration, molecular types, and information on collaborations, licensing, mergers and acquisitions, and discontinued development programs.
The data show that candidate assets named in the pipeline include trastuzumab pamirtecan (BNT-323), IBI354, BB-1701, HLX22, and ELVN-002. The related companies span major pharmaceutical firms and biotech companies in Asia, Europe, and the United States, including BioNTech, Innovent Biologics, Shanghai Henlius Biotech, Eisai, Bliss Biopharmaceutical, Roche, Novartis, Johnson & Johnson, Jazz Pharmaceuticals, Zymeworks, Enliven Therapeutics, and Mersana Therapeutics. Because the public summary does not provide the latest trial results or complete efficacy data for each drug, these names are better understood as an index of pipeline momentum rather than evidence that the clinical winners have already been determined.
The research and development boom in HER2-positive breast cancer has a clear medical logic behind it. HER2 is a growth-signaling receptor on the surface of tumor cells, and when it is overexpressed, it drives cancer cell proliferation. Therefore, anti-HER2 antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates approach the disease from different directions, respectively blocking signaling, inhibiting enzyme activity, or carrying cytotoxic drugs into tumor cells. Advances in antibody-drug conjugates in recent years have also made HER2 not only a signaling switch, but also a positioning marker for drug delivery.
However, a large pipeline does not mean that clinical breakthroughs are already in hand. HER2-positive breast cancer already has established treatment sequences. If new drugs are to secure a place, they usually must show clear benefit after existing standard therapies, or provide more convincing safety, convenience, or brain disease control data in specific populations. For patients, the real key is not the number of candidate drugs, but which drugs can prove in rigorous trials that they bring measurable improvements in survival, quality of life, or tolerability beyond current options.
This also makes regulatory and commercial challenges more complex. When multiple drugs are already competing around the same target, clinical trial design must answer more precise questions: what the comparator is, which HER2 therapies patients previously received, whether the tumor has heterogeneity or decreased HER2 expression, and whether safety signals will limit long-term use. Public information is currently more oriented toward market and pipeline overviews, and is not yet sufficient to judge which type of technology platform will become the next mainstream approach.
This wave of accelerated research and development still has significance as an indicator. HER2-positive breast cancer is no longer just a story of single-target therapy, but has entered a stage of competition across multiple platforms, multiple companies, and multiple lines of treatment. It reflects the next layer of reality after precision medicine matures: when first-generation successful drugs already exist, innovation must prove itself in narrower, more difficult gaps that are also closer to patients’ clinical circumstances.